NovaBridge Biosciences (NBP) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 3.0% versus a loss of 80.4%. Over five years, PDSB leads with a -92.5% price change compared with -98.7% for NBP. NovaBridge Biosciences is the larger company by market cap ($96.3 million vs $95.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | PDSB |
|---|---|---|
| Share price | $0.83 | $0.7774 |
| Market cap | $96.28M | $95.39M |
| 1-day change | -5.66% | -3.70% |
| YTD return | -79.15% | +0.96% |
| 1-year return | -80.38% | +2.97% |
| 5-year return | -98.69% | -92.46% |
| EPS (TTM) | $-0.69 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-46.27M | $-34.50M |
| 52-week high | $5.19 | $1.79 |
| 52-week low | $0.751 | $0.195 |
| Distance from 52-week high | -84.01% | -56.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +944.58% | +478.85% |
| Average volume | 515.66K | 25.64M |
| Shares outstanding | 116.00M | 122.70M |
| Employees | 30 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed NBP by 83.3 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NBP vs PDSB FAQ
Which is bigger, NovaBridge Biosciences or PDS Biotechnology?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $96.28M compared with $95.39M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, NBP or PDSB?
PDSB returned +2.97% over the past 12 months, compared with -80.38% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.